Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents.

Copper-64, a positron emitter suitable for positron emission tomography (PET), demonstrates improved in vivo clearance when chelated by the cross-bridged tetraazamacrocycle CB-TE2A compared to TETA. Good in vivo clearance was also observed for 64Cu-CB-TE2A conjugated to a peptide, which converts one coordinating carboxylate pendant arm to an amide. To better understand the in vivo stability of peptide- conjugated CB-TE2A, cross-bridged monoamides were synthesized. Crystal structures of natCu(II)-CB-TEAMA and natCu(II)-CB-PhTEAMA revealed hexadentate, distorted octahedral coordination geometry. In vivo biodistribution showed clearance of all 64Cu-radiolabeled cross-bridged monoamides from liver and bone marrow such that uptake at 24 h was <10% of uptake at 30 min. In contrast, >60% of 30 min uptake from 64Cu-TETA was retained in these tissues at 24 h. Clearance of 64Cu-cross-bridged monoamides from nontarget organs suggests good in vivo stability, thus supporting the use of CB-TE2A as a bifunctional chelator without modifications to the macrocycle backbone.

[1]  L. Zakharov,et al.  Kinetic Inertness and Electrochemical Behavior of Copper(II) Tetraazamacrocyclic Complexes: Possible Implications for in Vivo Stability , 2005 .

[2]  S. Achilefu,et al.  Preparation and Biological Evaluation of Copper-64–Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator , 2004, Clinical Cancer Research.

[3]  R. Boyle,et al.  Ultrastable complexes for in vivo use: a bifunctional chelator incorporating a cross-bridged macrocycle. , 2004, Chemical communications.

[4]  Weijun Niu,et al.  Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. , 2004, Journal of medicinal chemistry.

[5]  Joonyoung Kim,et al.  MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. , 2003, Bioconjugate chemistry.

[6]  D. Busch,et al.  Synthesis, structure, and stability in acid of copper(II) and zinc(II) complexes of cross-bridged tetraazamacrocycles , 2003 .

[7]  S. Ametamey,et al.  Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. , 2003, Nuclear medicine and biology.

[8]  Joonyoung Kim,et al.  DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. , 2002, Bioconjugate chemistry.

[9]  M. Wuest,et al.  Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. , 2002, Journal of medicinal chemistry.

[10]  R Laforest,et al.  64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Daniel C. Hill,et al.  Synthesis and Characterization of Cross-Bridged Cyclams and Pendant-Armed Derivatives and Structural Studies of Their Copper(II) Complexes , 2000 .

[12]  S S Gambhir,et al.  High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Welch,et al.  In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. , 2000, Bioconjugate chemistry.

[14]  David E Reichert,et al.  Labeling and in vivo evaluation of novel copper(II) dioxotetraazamacrocyclic complexes. , 2000, Nuclear medicine and biology.

[15]  P. Cutler,et al.  Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  D. Busch,et al.  Crystallographic Characterization of Stepwise Changes in Ligand Conformations as Their Internal Topology Changes and Two Novel Cross-Bridged Tetraazamacrocyclic Copper(II) Complexes. , 1999, Inorganic chemistry.

[17]  G. Denardo,et al.  Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. , 1999, Nuclear medicine and biology.

[18]  J. Lewis,et al.  In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. , 1999, Nuclear medicine and biology.

[19]  M. Welch,et al.  The in vivo behavior of copper-64-labeled azamacrocyclic complexes. , 1998, Nuclear medicine and biology.

[20]  J. Erion,et al.  Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide. , 1998, Bioconjugate chemistry.

[21]  E P Krenning,et al.  Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. , 1998, Cancer research.

[22]  T. Visser,et al.  Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy , 1997, European Journal of Nuclear Medicine.

[23]  M. Welch,et al.  Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. , 1996, Bioconjugate chemistry.

[24]  M. Welch,et al.  Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Rogers,et al.  Cross-bridged cyclam. Protonation and lithium cation (Li+) complexation in a diamond-lattice cleft , 1990 .

[26]  S. Denardo,et al.  Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. , 1985, Analytical biochemistry.

[27]  C. Anderson,et al.  Optimization of labeling and metabolite analysis of copper-64-labeled azamacrocyclic chelators by radio-LC-MS. , 2005, Nuclear medicine and biology.

[28]  D. Busch,et al.  Ultra rigid cross-bridged tetraazamacrocycles as ligands—the challenge and the solution , 1998 .

[29]  M J Welch,et al.  Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.

[30]  Daniel C. Hill,et al.  Synthesis and transition-metal complexes of new cross-bridged tetraamine ligands , 1996 .

[31]  G. Denardo,et al.  Comparative serum stability of radiochelates for antibody radiopharmaceuticals. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  G. Denardo,et al.  Serum stability of 67Cu chelates: comparison with 111In and 57Co. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.